Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Neurofibromatosis 1 3Neurofibromatoses 3Neurofibroma, Plexiform 2Neurofibroma 2Glioma 2Oligodendroglioma 1Neurocytoma 1Neoplasms, Neuroepithelial 1NF1 1Melanoma 1Glioblastoma 1Ganglioneuroma 1Ganglioglioma 1Central Nervous System Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 159Bevacizumab 69Radiotherapy 68Magnetic Resonance Spectroscopy 68Irinotecan 31Surgical Procedures, Operative 27Radiation 24Carboplatin 23Specimen Handling 20Carmustine 20Blood Specimen Collection 20Nivolumab 19Aminolevulinic Acid 18Biopsy 17Lomustine 16pembrolizumab 13Radiotherapy, Intensity-Modulated 13Cyclophosphamide 13trametinib 12fluorodopa F 18 12X-Rays 12Radiosurgery 12Erlotinib Hydrochloride 12Topotecan 11Everolimus 11Magnetic Resonance Imaging 10IL13-PE38 10dabrafenib 9Etoposide 9Drug Therapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Glioma × mirdametinib × CNS × Clear all
NCT07539441 2026-05-13

A Study of Mirdametinib in People With Central Nervous System Tumors

Memorial Sloan Kettering Cancer Center

Phase 1/2 Recruiting
26 enrolled
CNS

Glioma, Central Nervous System Neoplasms

NCT07521657 2026-04-13

NF118

University of Alabama at Birmingham

Phase 2 Not yet recruiting
55 enrolled
CNS

Glioblastoma, Glioma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡